BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

EDX Medical and Caris Life Sciences Forge Partnership for Advanced Molecular Profiling

NextEdge Admin

03 Sep 2024

2 min 19 sec

AI,precision medicine,molecular,EDX Medical

EDX Medical Group has entered into an exclusive distribution partnership with Caris Life Sciences, a leading US provider of next-generation AI TechBio and precision medicine. This collaboration will focus on bringing Caris' advanced molecular profiling services to the UK and Nordic countries, including Sweden, Denmark, Norway, and Finland.

Caris' molecular profiling leverages comprehensive DNA, RNA, and protein assessments to create detailed molecular blueprints of patients' cancers. These blueprints enable physicians to tailor treatment options to each patient, enhancing the effectiveness of cancer therapies.

The agreement, set for a minimum of three years, marks a significant step for EDX Medical in expanding its offerings of world-class diagnostic tools. Sir Chris Evans, founder of EDX Medical, highlighted the importance of this collaboration, stating, "For cancer patients who may only provide one sample and require urgent, optimal treatment, comprehensive analysis of the whole exome and transcriptome is the most robust clinical approach. We could not wish for a better partner than Caris in this field."

Caris Life Sciences will provide solid tumour and liquid biopsy analyses, as well as AI solutions, through EDX Medical’s distribution network. Dr. David Spetzler, President of Caris Life Sciences, expressed enthusiasm about the partnership, emphasizing its alignment with Caris’ mission to help clinicians worldwide make individualized treatment decisions and improve patient outcomes.

EDX Medical also recently launched a diagnostic tool in the UK to assess patients’ risk of developing hereditary cancer.